

Recombinant Human His8 USP7

Catalog Number: E-519

RDsystems

Source	
M A	Spodoptera frugiperda, Sf 21 (baculovirus)-derived human USP7 protein Aet1 - Asn1102 with a N-terminal 8-His tag Accession # Q93009.2
Predicted Molecular 13 Mass	30 kDa

SPECIFICATIONS	
Activity	Recombinant Human His8-USP7 is a Ubiquitin-specific deconjugating enzyme. Reaction conditions will need to be optimized for each specific application. We recommend an initial Recombinant Human His8-USP7 concentration of 1-5 nM.
Purity	>95%, by SDS-PAGE under reducing conditions and visualized by Colloidal Coomassie® Blue stain.
Formulation	Supplied as a 0.2 µm filtered solution in HEPES, NaCI, EDTA, DTT, and Glycerol. See Certificate of Analysis for details.

PREPARATION AND STORAGE	
Shipping	The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
	 6 months from date of receipt, -70 °C as supplied.
	 3 months70 °C under sterile conditions after opening.

BACKGROUND

Ubiquitin Specific Peptidase 7 (USP7), also known as Herpes Virus-associated Ubiquitin Specific Protease (HAUSP), is a widely expressed deubiquitinating enzyme belonging to the peptidase C19 family (1). It has a predicted molecular weight of 130 kDa (2). Human USP7 is 1102 amino acids (aa) in length and shares 99% aa sequence identity with the mouse and rat orthologs (2,3). USP7 consists of a cysteine peptidase core (aa 208-560) that is flanked by an N-terminal TRAF-like domain (aa 50-205) and two C-terminal protease-resistant domains (aa 622-801 and 885-1061) (2,3). USP7 can be phosphorylated at Ser18 and Ser963 and ubiquitinated at Lys869 (2,4). USP7 also targets the p53 regulatory proteins MDM2, MDMX, and Daxx, the epigenetic regulator Histone 2B, and the transcription factor FoxO4 (4,6-10). Additionally, USP7 interacts with the HSV-1 immediate early protein ICP0, contributing to the stabilization and transactivation capability of ICP0 during HSV-1 infection (1,11,12).

References:

- 1. Everett, R.D. et al. (1997) EMBO J. 16:1519.
- 2. Fernández-Montalván, A. et al. (2007) FEBS J. 274:4256.
- 3. Holowaty, M.N. et al. (2003) J. Biol. Chem. 278:47753.
- 4. Khoronenkova, S.V. et al. (2012) Mol. Cell 45:801.
- 5. Li, M. et al. (2002) Nature 416:648.
- 6. Brooks, C.L. & W. Gu (2004) Cell Cycle 3:895.
- 7. Meulmeester, E. et al. (2005) Cell Cycle 4:1166.
- 8. Tanga, J. et al. (2010) Biochem. Biophys. Res. Commun. 393:542.
- 9. van der Knaap, J.A. *et al.* (2005) Mol. Cell **17**:695.
- 10. van der Horst, A. et al. (2006) Nat. Cell Biol. 8:1043.
- 11. Everett, R.D. et al. (1999) J. Virol. 73:417.
- 12. Boutell, C. et al. (2005) J. Virol. 79:12342.

Rev. 11/27/2023 Page 1 of 1



Global bio-techne.com info@bio-techne.com techsupport@bio-techne.com TEL +1 612 379 2956 USA TEL 800 343 7475 Canada TEL 855 668 8722 China TEL +86 (21) 52380373 Europe | Middle East | Africa TEL +44 (0)1235 529449